Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

被引：0
|
作者：
Samuel Murray
Vasilios Karavasilis
Mattheos Bobos
Evangelia Razis
Savvas Papadopoulos
Christos Christodoulou
Paris Kosmidis
George Fountzilas
机构：
[1] BioMarker Solutions Ltd,Department of Molecular Oncology
[2] GeneKOR,Department of Medical Oncology
[3] “Papageorgiou” Hospital,Department of Pathology
[4] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology
[5] Aristotle University of Thessaloniki School of Medicine,Department of Pathology
[6] “Hygeia” Hospital,Second Department of Medical Oncology
[7] “Hygeia” Hospital,Second Department of Medical Oncology
[8] “Metropolitan” Hospital,undefined
[9] “Hygeia” Hospital,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 31卷
关键词：
Predictive; Somatic mutation; EGFR; Gefitinib; Erlotinib; Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms
    Shiba-Ishii, Aya
    Takemura, Noriko
    Kawai, Hitomi
    Matsubara, Daisuke
    CANCER SCIENCE, 2024, 115 (07) : 2138 - 2146
  • [12] Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
    Zucali, P. A.
    Ruiz, M. G.
    Giovannetti, E.
    Destro, A.
    Varella-Garcia, M.
    Floor, K.
    Ceresoli, G. L.
    Rodriguez, J. A.
    Garassino, I.
    Comoglio, P.
    Roncalli, M.
    Santoro, A.
    Giaccone, G.
    ANNALS OF ONCOLOGY, 2008, 19 (09) : 1605 - 1612
  • [13] Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors
    Dogan, Izzet
    Khanmammadov, Nijat
    Yildiz, Anil
    Ahmed, Melin Aydan
    Vatansever, Sezai
    Saip, Pinar
    Aydiner, Adnan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (07) : 1945 - 1949
  • [14] Clinical Predictors of Response to EGFR Tyrosine Kinase inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Fukihara, Jun
    Watanabe, Naohiro
    Taniguchi, Hiroyuki
    Kondoh, Yasuhiro
    Kimura, Tomoki
    Kataoka, Kensuke
    Matsuda, Toshiaki
    Yokoyama, Toshiki
    Hasegawa, Yoshinori
    ONCOLOGY, 2014, 86 (02) : 86 - 93
  • [15] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
    Liao, Bin-Chi
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Chen, Ya-Fang
    Chang, Chin-Hao
    Ho, Chao-Chi
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) : 1754 - 1761
  • [16] Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer
    Tinsley, N.
    Zhou, C.
    Nahm, S.
    Rack, S.
    Tan, G. C. L.
    Lorigan, P.
    Blackhall, F.
    Cook, N.
    ESMO OPEN, 2022, 7 (03)
  • [17] Assessment of efficacy and safety of MET tyrosine kinase inhibitors in non-small-cell lung cancer patients with MET alterations
    Wang, Yanhua
    Xu, Manyi
    Wang, Ke
    Hao, Yue
    Xu, Chunwei
    Song, Zhengbo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [18] Pyrimidine derivatives as EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: A comprehensive review
    Kizhakkedath Ratheesh, Anandu
    Pottankottu Jayan, Ajay
    Presanna, Aneesh Thankappan
    Nirmala, Saiprabha Vijayakumar
    CHEMICAL BIOLOGY & DRUG DESIGN, 2022, 100 (04) : 599 - 621
  • [19] Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
    Kim, Toe-You
    Han, Soe-Won
    Bang, Yung-Jue
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2007, 7 (06) : 821 - 836
  • [20] Potential Efficacy of Multi-targeted Tyrosine Kinase Inhibitors in Non-small-cell Lung Cancer
    Chen, Jinfei
    BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (05) : 322 - 322
12345